c-Myb is a crucial transcription factor that participates in various biological functions; however, its role in colorectal cancer (CRC) remains poorly investigated. We first analyzed the expression and clinical significance of c-Myb in a retrospective cohort enrolling 132 CRC patients. Then, the CRISPR/Cas9 technique was used to establish c-Myb gene KO CRC cell lines. Cellular functional assays in vitro and in vivo were used to evaluate the impact of c-Myb KO in CRC cells. Finally, RNA sequencing was used to investigate the potential oncogenic mechanisms regulated by c-Myb in CRC progression and related cellular validations were accordingly carried out. As a result, c-Myb is significantly overexpressed in CRC tissues as compared with adjacent normal tissues. High expression of c-Myb is positively correlated with lymph node metastasis and poor prognosis. Univariate analysis and multivariate analysis further identify c-Myb as an independent unfavorable prognostic factor for CRC patients. c-Myb KO inhibits the proliferation, apoptosis resistance, invasion, metastasis, colony formation and in vivo tumorigenesis of CRC cells. Also, the mechanism investigation indicates that c-Myb may promote CRC progression by regulating c-fos. c-fos overexpression can rescue the inhibitory effect of c-Myb KO on the malignant characteristics of CRC cells. Finally, we find that c-Myb KO inhibits the epithelial-mesenchymal transition (EMT) molecular phenotype in CRC cells, whereas c-fos overexpression can rescue this inhibitory effect. This study suggests that c-Myb promotes the malignant progression of CRC through c-fos-induced EMT and has the potential to be a promising prognostic biomarker and therapeutic target. K E Y W O R D S biomarker, c-fos, c-Myb, colorectal cancer, epithelial-mesenchymal transition
| INTRODUC TI ON
Colorectal cancer is one of the most common causes of cancerrelated death worldwide. 1 The pathogenesis of CRC is currently thought to be a complicated, multistep process involving multigene regulation. 2 Therefore, a thorough understanding of CRC molecular pathogenesis may benefit the discovery of novel diagnostic markers or therapeutic targets that can improve individualized CRC management strategy.
The protein, c-Myb, a member of the Myb protein family, is a transcription factor that participates in regulating cell cycle, differentiation and proliferation through DNA binding. 3 It is reported to be involved in maintaining colonic crypt homeostasis, which is related to its regulatory role in crypt proliferation, integrity and normal differentiation. 4 Although it was originally described to be hematopoietic lineage-specific, increasing studies have found it is overexpressed in numerous solid tumors and may contribute to the malignant characteristics of cancer cells. 5 For example, c-Myb is able to drive the invasion and metastasis of breast cancer cells through the Wnt/β-Catenin/Axin2 signaling pathway. 6 In liver cancer, it transcriptionally regulates the expression of Yes-associated protein (YAP) to promote the growth of cancer cells in vivo and in vitro. 7 A recent review has attributed its oncogenic role to its interaction with cell cycle proteins, protein kinases and other transcription factors. 8 Previously, we have proven that microRNA-150 suppressed the malignant characteristics of CRC cells by negatively regulating c-Myb. 9 However, the specific clinical significance and biological role of c-Myb in CRC remain poorly studied. Therefore, in the present study, we first detected its expression and analyzed its clinical significance in a retrospective CRC cohort. Then, we established c-Myb gene KO CRC cell lines and accordingly carried out functional validations in vitro and in vivo. Finally, RNA sequencing was used to investigate the potential oncogenic mechanisms regulated by c-Myb in CRC progression and its results were subsequently confirmed by molecular assays.
| MATERIAL S AND ME THODS

| Patient data
For details, please see Appendix S1. This study was approved by the ethics committees of Shanghai Tongji University Affiliated Tenth People's Hospital, and informed consents have been acquired.
| Immunohistochemical staining and scoring
For details, please see Appendix S1.
| Cell culture
| Real-time polymerase chain reaction
For details, please see Appendix S1. All the primer sequences are shown in Table S1 .
| Western blot
| Terminal deoxynucleotidyl transferasemediated dUTP nick end labeling analysis
| Cell counting kit-8 assay
| Apoptosis assay
| Transwell migration and invasion assay
| Colony formation assay
| CRISPR/Cas9 technique
Gene KO was carried out using CRISPR/Cas9. Single-guide RNA (sgRNA) was designed based on the following sequence: 5′-AGTCTGGAAAGCGTCACTTG-3′ and then its vector was constructed. Lentiviral packaging was done using two plasmids, which contain Cas9 and sgRNA, respectively. KO cells and NC cells were selected by puromycin. Lentivirus also carries GFP for monitoring transfection efficiency.
| Plasmid construction
| Xenograft model
| RNA sequencing
| Chromatin immunoprecipitation
Crosslinking of DNA and proteins was carried out by adding formaldehyde to CRC cells and terminated using glycine. Samples were lysed using lysis buffer and transferred to ultrasound disruption using a Bioruptor Plus sonicator (Diagenode). After DNA purification, the input DNA control samples were prepared. The acquired chromatin fragments were transferred to immunoprecipitation using Dynabeads Protein A magnetic beads (Multi Sciences) and the primary antibody against c-Myb. After protein digestion, the purified DNA was transferred to PCR using the following PCR primers that were designed for the promoter region of c-fos: forward: GCTGCAGCCCGCGAGCAG; reverse: AATCTCGT GAGCATTTCG.
| Dual-luciferase reporter assay
The binding site of c-Myb on the c-fos promoter was analyzed using an online transcription factor prediction program ( http://consi te.gener eg.net/). c-fos promoter (c-fos-p) construct contained the c-Myb-binding sites 1 (c-fos-p site 1: -149~-143).
Sequences for the c-fos promoter containing the binding site were designed as follows: wild type (WT) c-fos promoter: 5′-CCTCTGAGACAGGAACTGCG-3′; mutant type (MT) c-fos promoter: 5′-CCTCTGAGACAGGGATTATG-3′. Dual-luciferase reporter assay was carried out using the Dual-luciferase Reporter assay kit (Promega).
| Statistical analysis
| RE SULTS
| Expression and clinical significance of c-Myb in CRC patients
First, we used RT-PCR ( Figure 1A A, RT-PCR shows that the mRNA level of the c-Myb gene was significantly higher in CRC tissues than that in matched adjacent normal tissues (n = 20, P = .005). B, Western blot shows that the protein level of c-Myb was higher in CRC tissues than that in matched adjacent normal tissues (n = 20, P = .008). C, Representative protein bands of c-Myb and GAPDH. D, Representative immunohistochemical staining images of c-Myb in CRC and matched adjacent normal tissues. E, Cut-off value of immunohistochemical staining scores is determined by receiver operating characteristic curve analysis. **P < .01 of c-Myb is significantly higher in CRC tissues than in adjacent normal tissues both at mRNA and protein level. In addition, we used immunohistochemistry to detect its expression in the CRC and paired adjacent normal tissues from a retrospective cohort enrolling 132 patients. Representative staining results are shown in Figure 1D .
Using the semiquantitative scoring and ROC analysis, we determined that the cut-off value of staining scores was 3.5 ( Figure 1E ). Therefore, based on this threshold, the entire cohort was divided into a high-expression group (n = 71) and a low-expression group (n = 61). Table 1 , we found that c-Myb expression was sig- Figure 2A ). Subgroup analysis based on TNM staging also showed that c-Myb expression could stratify the OS and DFS of CRC patients both in stage II and in stage III (all P < .01, Figure 2B ,C). Univariate analysis indicated that both lymph node metastasis and c-Myb expression were significant factors for OS and DFS (all P < .01, Table 2 ). Multivariate analysis indicated that they were also independent prognostic factors for OS and DFS (all P < .01, Table 3 ).
As shown in
| Knockout of c-Myb inhibits the malignant characteristics of CRC cells in vitro
First, we used RT-PCR to detect c-Myb expression in five commonly used CRC cell lines (HCT116, SW620, HT29, LOVO, and SW480) and one normal intestinal epithelial cell line (HIEC-6). As a result, we found that the mRNA level of c-Myb was significantly higher in CRC cell lines compared with the normal intestinal epithelial cell line, and was relatively abundant in HCT116 and SW620 cell lines ( Figure 3A ).
Then, we carried out the CRISPR/Cas9 technique to KO c-Myb expression in both the cell lines and western blot confirmed its KO efficiency ( Figure 3B ).
Next, we carried out functional assays in vitro to assess the impact of c-Myb KO on the malignant characteristics of CRC cells.
First, in the CCK8 assay, we found c-Myb KO significantly inhibited the proliferation of HCT116 and SW620 cells ( Figure 3C ). Apoptosis assay showed that c-Myb KO dramatically increased the apoptosis rate of HCT116 and SW620 cells ( Figure 3D ). Moreover, in the colony formation assay, c-Myb KO was found to reduce the number of colonies in HCT116 and SW620 cells ( Figure 3E ). Finally, Transwell assay showed that c-Myb KO also inhibited the migratory and invasive ability of CRC cells ( Figure 3F ,G). Taken together, these results suggested that c-Myb KO effectively inhibited the malignant characteristics of CRC cells in vitro.
| Knockout of c-Myb inhibits the growth of CRC cells in vivo
To assess the impact of c-Myb KO on the growth of CRC cells in vivo, we established a xenograft model by injecting CRC cells s.c.
into the right hind of nude mice. Harvested tumors are shown in Figure 4A , and we found that size of tumors in the NC group was significantly larger than that in the KO group. Growth curve showed that c-Myb KO significantly inhibited the growth of xenografts ( Figure 4B ). In addition, we also found that weights of tumors in the NC group were significantly greater than those in the KO group ( Figure 4C ). We also carried out immunohistochemical staining to detect proliferating cell nuclear antigen (PCNA) expression in the harvested tumors and the results showed that c-Myb KO significantly reduced its positive rate in tumor cells ( Figure 4D ). Finally, using TUNEL assay, we found c-Myb KO remarkably increased the apoptotic rate of tumor cells ( Figure 4E ). Taken together, these data suggested that c-Myb KO also effectively inhibited the growth of CRC cells in vivo. 
TA B L E 1 Correlations between c-Myb expression and clinicopathological characteristics in CRC patients
| c-Myb promotes CRC progression by regulating c-fos
To further explore the molecular mechanisms regulated by c-Myb in CRC development, RNA-seq was first used to discover significantly expressed genes between the KO group and its negative control in Figure 5D ). Then, Cytoscape software was used to predict the interaction between c-Myb and those genes. Results suggested that only the c-fos gene appeared to have an interaction with c-Myb ( Figure 6A ). We carried out RT-PCR ( Figure 6B 
| Overexpression of c-fos rescues the inhibitory effect of c-Myb KO on the malignant characteristics of CRC cells in vitro
To further confirm whether c-fos is responsible for the oncogenic role of c-Myb, we constructed plasmids to upregulate c-fos expression in c-Myb KO CRC cells. Overexpression efficiency of constructed plasmids was validated by RT-PCR ( Figure 7A ) and western blot ( Figure 7B ).
In the CCK-8 assay, c-fos overexpression effectively accelerated the proliferation of c-Myb KO HCT116 and SW620 cells ( Figure 7C ). In the apoptosis assay, c-fos overexpression significantly decreased the apoptosis rate of c-Myb KO HCT116 and SW620 cells ( Figure 7D ).
Transwell assay showed c-fos overexpression significantly promoted the migratory and invasive ability of c-Myb KO HCT116 and SW620 cells ( Figure 7E,F) . Finally, colony formation assay indicated c-fos overexpression also increased the colony numbers of c-Myb KO HCT116 and SW620 cells ( Figure 7G ). Taken together, these results collectively suggested that c-fos overexpression effectively rescued the inhibitory effect of c-Myb KO on the malignant characteristics of CRC cells in vitro.
F I G U R E 3 Knockout of c-Myb inhibits the malignant characteristics of colorectal carcinoma (CRC) cells in vitro.
A, RT-PCR shows that the mRNA level of the c-Myb gene is higher in CRC cell lines compared with normal intestinal epithelial cells. B, Western blot shows that protein expression of c-Myb is significantly lower in the KO group than in the negative control (NC) group. C, Optical density value of the KO group increased more slowly than that of the NC group within 5 d. D, Apoptosis rates of the KO group are higher than that of the NC group. E, Colony numbers of the KO group are lower than that of the NC group. F, Numbers of migratory cells in the KO group are lower than that in the NC group. G, Numbers of invasive cells in the KO group are lower than that in the NC group. *P < .05, **P < .01, ***P < .001, ****P < .0001. Error bar represents standard deviation, n = 3
| Overexpression of c-fos rescues the inhibitory effect of c-Myb KO in the EMT phenotype
As EMT is a crucial molecular mechanism regulating CRC growth and metastasis, we used western blot to detect its representative markers (snail, E-cadherin, N-cadherin, Vimentin) in CRC cells (Figure 8 ). In this study, we first detected the expression of c-Myb in CRC and its matched adjacent normal tissues. We found its expression was significantly higher in CRC tissues, which is in accordance with previous observations in other tumors including laryngeal, 14 nasopharyngeal, 15 and gallbladder. 16 Correlation analysis showed that c-Myb expression was associated with lymph node metastasis, implying its potential participation in CRC metastasis. To identify its prognostic significance, we constructed Kaplan-Meier survival curves based on follow-up data. We found patients with high c- Taken together, these findings strongly suggest that c-Myb promotes the malignant progression of CRC through regulating c-fos.
| D ISCUSS I ON
It is well established that EMT is a crucial molecular mechanism involved in tumor growth and metastasis. 27 Molecularly, the EMT phenotype is characterized by downregulation of epithelial markers (E-cadherin) and upregulation of mesenchymal markers (N-cadherin, Vimentin and snail). 28, 29 In hepatocellular carcinoma, c-Myb functions as a target of long non-coding RNA downregulated in hepatocellular carcinoma (DRHC) to promote the EMT phenotype through the MEK/ERK signaling pathway. 30 c-Myb could also cooperate with transforming growth factor beta (TGF-β) to enhance the EMT phenotype of estrogen(+) breast cancer cells. 31 Meanwhile, c-fos has been proven to induce EMT as well as the stem cell phenotype of head and neck squamous cell carcinoma. 32 
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